GMRSGMR Solutions Inc.
The schedule
- Thu15Oct
Management update on restructuring the 4.46x Net Debt/EBITDA leverage. Successful term extensions target $13.50, but dilution risk creates a $6.50 fallback.
- Wed25Nov
Q3 print to reveal operational cash generation post-restructuring. Upside targets $9.00, while a miss threatens a $4.50 fallback.
- Mon30Nov
Q2 earnings focus on operating cash flow to service the massive debt load. Bull target is $15.00, but a miss risks a plunge to the $9.50 fallback.
- Wed20Jan
Anticipated deregulatory mandates from President Trump's administration. Constructive policy targets $7.50, while delayed relief risks a $3.00 fallback.
- Tue2Mar
Full-year results and 2027 outlook leveraging new policy tailwinds. Strong guidance targets $10.50, while sustained cash burn risks a $5.00 fallback.
Past
- Mon3Aug
Actual outcome: Bear
The final CMS Fiscal Year 2027 IPPS rule established lower-than-expected reimbursement rates and unfavorable payment updates for the company's core procedures. This lack of adequate Medicare pricing support signaled upcoming margin pressure and reduced revenue visibility, driving the stock below the bear floor.
Release of the final Medicare Inpatient Prospective Payment System (IPPS) reimbursement rates by CMS.
